ImmunityBio, Inc.
Moat Score — ImmunityBio, Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | ImmunityBio holds a genuine first-in-class position with ANKTIVA, the first FDA-approved IL-15 receptor superagonist, backed by a broad underlying patent estate spanning its cytokine-fusion, hAd5 viral-vector, and NK-cell (aNK/haNK/t-haNK) platforms across nine first-in-human agents. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | ImmunityBio is far from a low-cost operation — its $413.6 million 2024 net loss against only $14.15 million of product revenue reflects the heavy cost of clinical development, commercial launch, and complex biologic manufacturing, with no cost advantage versus peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | ANKTIVA's narrow, serious indication (BCG-unresponsive NMIBC with CIS), permanent J-code reimbursement, and coverage across more than 240 million insured lives support real pricing power for a newly launched biologic, though broader payer negotiation dynamics in oncology ultimately constrain it. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | ImmunityBio's business is a traditional biopharmaceutical commercialization model with no network effect — ANKTIVA's value to one patient or physician does not increase because other patients or physicians are also using it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a urology practice has integrated ANKTIVA into its BCG-unresponsive NMIBC treatment protocol, switching away mid-treatment carries real clinical and administrative friction, but ImmunityBio's commercial base is still small and newly established, limiting how much embedded switching cost currently exists. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The chronic BCG supply shortage — driven largely by Merck's dominant legacy position — has created a narrow but real opening that few competitors can fill quickly, and ImmunityBio's Serum Institute rBCG partnership plus its approved ANKTIVA combination give it a defensible foothold in that specific niche. |